Led by B2H, the CHU de Liège and the ULg have launched their collaboration with Janssen Pharmaceutica

Led by B2H, the CHU de Liège and the ULg have launched their collaboration with Janssen Pharmaceutica

The University of Liège (ULg), the Centre Hospitalier Universitaire (CHU) de Liège, Janssen Pharmaceutica and Janssen-Cilag have signed on February 2nd a charter to launch their collaboration, aiming at strengthening their mutual competences in the setting-up and execution of multidisciplinary research projects and thus, accelerating patient access to medical innovations.

The objective is to promote the operational networking of academic, hospital and industrial expertise in five medical innovation domains:

  1. Acceleration and optimization of clinical research through access to a pan-European project facilitating the exchange of data between research centers
  2. Intensification of Phase I research of new drugs for cancer, type II diabetes, Alzheimer’s disease, rheumatoid arthritis and psoriasis
  3. Interdisciplinary collaboration and exchange of technological and scientific knowledge in drug development and production
  4. Collaboration for improved patient outcome by (1) developing the innovative concept of home hospitalization as a form of oncological patient care and (2) improving the healthcare pathway of cancerous patients
  5. Access to the JLINX investment and incubator model on the Janssen campus in Beerse

Picture © Michel Houet: from left to right, Tom Aelbrecht (Janssen Pharmaceutica), Pr. Rudi Cloots (ULg), Sonja Willems (Janssen Benelux), Julien Compère (CHU de Liège).

Related articles

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials

A new gene responsible for juvenile myoclonic epilepsy?

In collaboration with a team at the University of California at Los Angeles (UCLA), researchers from GIGA-Neurosciences have discovered a new gene responsible for a seizure syndrome called juvenile myoclonic epilepsy (JME). This discovery was made as part of an international consortium that studies genetic abnormalities responsible for epileptic diseases. It is being published this week in

Read more
A new gene responsible for juvenile myoclonic epilepsy?

New technologies available at the GIGA Imaging platform

The LIGHTSHEET MICROSCOPY can deliver optical sections, 3D reconstructions and timelapse movies of whole sample volumes at subcellular resolutions. The fast scan speeds and low phototoxicity of the lightsheet allow to record the development of fluorescent transgenic animals over long time periods, such as zebrafish embryos. Alternatively 3D reconstructions of fixed whole organs or whole embryos,

Read more
New technologies available at the GIGA Imaging platform

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.


We track anonymized user information to improve our website.
  • _ga 2 year
  • _gid 24 hours
  • _gat 1 minute
  • AMP_TOKEN 30 seconds to 1 year
  • _gac_ 90 days

Decline all Services
Accept all Services